Artificial Intelligence (AI)
Guidance, Education, Tools/Resources

ISMPP AI Position Statement and Call to Action

The ISMPP Position Statement and Call to Action on Artificial Intelligence (AI) was published on November 1, 2023, in Current Medical Research and Opinion (CMRO).¹

LEARN about the ISMPP AI Position Statement and Call to Action in The MAP newsletter. WATCH the ISMPP U webinar to hear about it from the ISMPP AI Task Force.

¹ International Society for Medical Publication Professionals (ISMPP) position statement and call to action on artificial intelligence. Curr Med Res and Opin. 2023; DOI: 10.1080/03007995.2023.2273139.

Checklist for the Use of AI to Generate a Manuscript from a Study Report

A Checklist has been created to support medical writers when using generative artificial intelligence (GenAI) to facilitate development of manuscripts in collaboration with authors. The checklist covers steps on the use of AI to develop kick-off call minutes, drafting content, as well as the quality control steps and the importance of human oversight throughout this process. The purpose of the checklist is to provide a guide to the essential steps; it may not be comprehensive and should be used in conjunction with Good Publication Practice and other relevant publication processes. It is hoped that this checklist will provide confidence and will support medical writers in the ethical and responsible use of GenAI.

LLM Overview

The LLM Overview provides ISMPP members with an overview of various large language models (LLMs) available as of August 2024, in an Excel sheet format. It compares their capabilities, such as writing, editing, and summarization, along with technical specifications like context windows and output limits. The analysis aims to assist ISMPP members in exploring these tools for research, data analysis, and content review, while emphasizing the importance of human oversight in their application. This resource is not a recommendation but serves as a starting point for understanding the landscape of AI technology in the field. The LLM Overview is accessible only to ISMPP members.

AI Lexicon

The AI Lexicon explains the most important AI-related terms for a medical writer audience. Feedback on the AI Lexicon can be emailed to [email protected].

AI Questions and Answers

The ISMPP AI Task Force provides answers to questions received from ISMPP members on its AI Questions and Answers web page. Email [email protected] to submit your questions related to AI in medical publications and communications.

ISMPP AI Task Force

Keith Goldman, Co-chair (AbbVie); Matt Lewis, Co-chair (Inizio); Chris Bendall (Research Solutions); Amy Foreman-Wykert (Amgen); Jason Gardner (Real Chemistry); Jenny Ghith (Pfizer); Richard Graves (Sorcero); Stephen Griffiths (GSK); Gary Lyons (Avalere Health); Monica Mody (Bristol Myers Squibb); Valerie Moss (Prime Global); Chirag Jay Patel (Cactus Global); Michael Platt (CEA/CCO); Bob Schijvenaars (Digital Science); Andy Shepherd (Envision Pharma); and Gary Dorrell, Ad-hoc Contributor (Pfizer).

All contents © 2024 International Society for Medical Publication Professionals, Inc. (ISMPP). ISMPP will grant limited permission to use materials developed by the AI Task Force for personal, non-commercial use. Such use is permitted only if you accept all of the terms and conditions contained in this nonexclusive, nontransferable, limited license agreement. Please read this license carefully before using this material in any manner.

By using these materials, you hereby accept and agree that: use of the material, and their content, shall be for individual, personal, and non-commercial reference and use only; and, the material shall be used only pursuant to the terms of this license agreement. The material, and their content, are proprietary information of ISMPP and/or the individual authors. The contents of the material may not, in whole or in part, be reproduced, copied, disseminated, or otherwise utilized, in any form or manner or by any means, except for individual, personal, and non-commercial reference and use.